At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Market Closed 04-02 16:00:00 EDT
4.14
+0.14
+3.50%
盘后4.14
+0.000.00%
16:04 EDT
High4.41Low3.91Vol72.26K
Open3.93D1 Closing4.00Amplitude12.50%
Mkt Cap38.31MTradable Cap20.43MTotal Shares9.25M
T/O302.27KT/O Rate1.46%Tradable Shares4.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CervoMed Posts Investor Presentation Under Regulation FD Disclosure
TIPRANKS  ·  03-24
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
Cervomed Inc. Publishes Presentation Factsheet
Reuters  ·  03-24
Cervomed Inc. Publishes Presentation Factsheet
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
TIPRANKS  ·  03-20
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
CervoMed Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  03-20
CervoMed Is Maintained at Buy by D. Boral Capital
BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed
Reuters  ·  03-19
BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed
CervoMed’s neflamapimod shows efficacy in dementia with DLB
TIPRANKS  ·  03-19
CervoMed’s neflamapimod shows efficacy in dementia with DLB
BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology
Reuters  ·  03-19
BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology
CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL
Reuters  ·  03-19
CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL
CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology
THOMSON REUTERS  ·  03-19
CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology
CervoMed Is Maintained at Buy by Chardan Capital
Dow Jones  ·  03-18
CervoMed Is Maintained at Buy by Chardan Capital
Chardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating
MT Newswires Live  ·  03-18
Chardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating
CervoMed price target lowered to $11 from $19 at Roth Capital
TIPRANKS  ·  03-18
CervoMed price target lowered to $11 from $19 at Roth Capital
Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)
TIPRANKS  ·  03-18
Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)
CervoMed price target raised to $21 from $15 at Chardan
TIPRANKS  ·  03-18
CervoMed price target raised to $21 from $15 at Chardan
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
TIPRANKS  ·  03-18
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
CervoMed FY2025 net loss rose 66.67% to USD 27 million
Reuters  ·  03-18
CervoMed FY2025 net loss rose 66.67% to USD 27 million
BRIEF-CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates
Reuters  ·  03-17
BRIEF-CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
TIPRANKS  ·  03-17
CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang
CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate
Benzinga  ·  03-17
CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate
Press Release: CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Dow Jones  ·  03-17
Press Release: CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--